• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design
Conclusions ISCHEMIA will provide new scientific evidence regarding whether an invasive management strategy improves clinical outcomes when added to optimal medical therapy in patients with SIHD and moderate or severe ischemia.
Source: American Heart Journal - May 26, 2018 Category: Cardiology Source Type: research

Non-eligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR)
Conclusion Most patients with STEMI not receiving reperfusion therapy had a documented reason. Coronary anatomy not suitable for PCI was the major contributor to ineligibility. In-hospital mortality was higher in patients not receiving reperfusion therapy.
Source: American Heart Journal - January 12, 2016 Category: Cardiology Source Type: research

None-ligibility for reperfusion therapy in patients presenting with ST-segment elevation myocardial infarction: Contemporary insights from the National Cardiovascular Data Registry (NCDR)
Conclusion Most patients with STEMI not receiving reperfusion therapy had a documented reason. Coronary anatomy not suitable for PCI was the major contributor to ineligibility. In-hospital mortality was higher in patients not receiving reperfusion therapy.
Source: American Heart Journal - November 25, 2015 Category: Cardiology Source Type: research

High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and improved outcomes in patients with coronary artery disease and reduced ejection fraction
Conclusions Reverse LV remodeling can occur after high-risk PCI in patients with complex coronary artery disease and reduced EF and is associated with improved clinical outcomes.
Source: American Heart Journal - September 15, 2015 Category: Cardiology Source Type: research

Prognosis of elderly patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention in 2001 to 2011: A report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) registry
Conclusions: The prognosis of patients older than 80 years treated with primary PCI for STEMI was relatively unchanged during the 10-year inclusion period, despite changes in patient characteristics and treatment. Advanced age increased the risk of adverse events, but survivors of the early phase after PCI had a slightly improved prognosis compared with the general population.
Source: American Heart Journal - February 27, 2014 Category: Cardiology Authors: Matthijs A. Velders, Stefan K. James, Berglind Libungan, Giovanna Sarno, Ole Fröbert, Jörg Carlsson, Martin J. Schalij, Per Albertsson, Bo Lagerqvist Tags: Acute Ischemic Heart Disease Source Type: research

Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: Design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post–Percutaneous Coronary Intervention (RIVER-PCI) trial
Conclusions: RIVER-PCI is a novel, large-scale, international, randomized, double-blind, placebo-controlled clinical trial evaluating the role of ranolazine in the long-term medical management of patients with ICR post-PCI.
Source: American Heart Journal - October 18, 2013 Category: Cardiology Authors: Giora Weisz, Ramin Farzaneh-Far, Ori Ben-Yehuda, Bernard DeBruyne, Gilles Montalescot, Amir Lerman, Ehtisham Mahmud, Karen P. Alexander, E. Magnus Ohman, Harvey D. White, Ann Olmsted, Gennyne A. Walker, Gregg W. Stone Tags: Trial Design Source Type: research